Literature DB >> 10472757

Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors.

M M Asgari1, J G Haggerty, J M McNiff, L M Milstone, P M Schwartz.   

Abstract

Thymidine phosphorylase/platelet-derived endothelial cell growth factor (TPase/PD-ECGF) is a catabolic enzyme that has been shown to be chemotactic for endothelial cells in vitro and angiogenic in vivo. TPase/PD-ECGF expression is increased in a variety of tumors. In the skin, TPase is active in normal keratinocytes in vitro and in vivo. Our objective was to study the expression and localization of TPase/PD-ECGF by immunohistochemical analysis in normal skin and cutaneous tumors and to correlate this information with enzymatic activity of TPase. TPase/PD-ECGF expression was observed in keratinocytes with intense staining of the infundibulum of hair follicles but no staining of hair bulbs. Expression localized primarily to the nucleus of keratinocytes in the basal layer but was more intense and cytoplasrmic in suprabasal keratinocytes. Increased expression of TPase/PD-ECGF in differentiated cells was confirmed by in vitro studies of TPase activity. In cutaneous tumors, there was positive staining for TPase/ PD-ECGF in squamous cell carcinomas (10/10), eccrine poromas (3/4), eccrine syringomas (4/4), trichoepitheliomas (1/3), and tumors of the follicular infundibulum (2/3) and melanomas (5/8). There was no staining of any intradermal nevi (0/2), basal cell carcinomas (0/10) or Merkel cell carcinoma (0/1). We conclude TPase/PD-ECGF is found throughout the epidermis and its expression increases with differentiation of keratinocytes. In cutaneous tumors, expression of TPase/PD-ECGF may be linked to the cell of origin of the tumor as well as the tumor's degree of differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10472757     DOI: 10.1111/j.1600-0560.1999.tb01846.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  8 in total

1.  Efficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving Capecitabine.

Authors:  Daigo Yamamoto; Chizuko Yamamoto; Satoru Iwase; Yujiro Kuroda; Hiroki Odagiri; Yoshinori Nagumo
Journal:  Breast Care (Basel)       Date:  2010-11-26       Impact factor: 2.860

2.  [Hand-foot syndrome with capecitabine therapy].

Authors:  A Marini; U R Hengge
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

3.  Candidate mechanisms for capecitabine-related hand-foot syndrome.

Authors:  Gérard Milano; Marie-Christine Etienne-Grimaldi; Mireille Mari; Sandra Lassalle; Jean-Louis Formento; Mireille Francoual; Jean-Philippe Lacour; Paul Hofman
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

4.  An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity?

Authors:  Biju Vasudevan
Journal:  Indian J Pharmacol       Date:  2010-10       Impact factor: 1.200

5.  Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical.

Authors:  Sepideh Elyasi; Sara Rasta; Ali Taghizadeh-Kermani; Sare Hosseini
Journal:  Daru       Date:  2022-03-23       Impact factor: 4.088

6.  Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: A case report.

Authors:  Masafumi Inokuchi; Satoko Ishikawa; Hiroyuki Furukawa; Hiroyuki Takamura; Itasu Ninomiya; Hirohisa Kitagawa; Sachio Fushida; Takashi Fujimura; Tetsuo Ohta
Journal:  Oncol Lett       Date:  2013-11-26       Impact factor: 2.967

7.  Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.

Authors:  Hyun-Sook Son; Woo Yong Lee; Won-Suk Lee; Seong Hyeon Yun; Ho-Kyung Chun
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

8.  Hand-foot syndrome with docetaxel: a five-case series.

Authors:  Mirna H Farhat; Nagi S El-Saghir; Ali I Shamseddine
Journal:  Ann Saudi Med       Date:  2008 Sep-Oct       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.